企業プロフィール
Halozyme Therapeutics, Inc. 株価・ニュース・カタリスト
- ティッカー:
- HALO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
106.94 USD (-3.13%)
終値
最終更新: 2026年10月1日
7.86B USD
時価総額
株価変動の要因
2026年10月1日 時点で HALO は 3.13% 下落し、$106.94 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Drug-Delivery Technology Company
Halozyme develops and licenses technologies that improve how biologic medicines are formulated and administered. Its business is based on platform access fees, development milestones, product supply, and royalties from partner medicines rather than ownership of most underlying therapeutic molecules.
ENHANZE Platform
ENHANZE uses recombinant human hyaluronidase PH20 to temporarily degrade hyaluronan in the subcutaneous space. This can enable large-volume subcutaneous delivery of therapies that would otherwise require intravenous infusion, reducing administration time and treatment burden.
Commercial Partner Products
The technology is incorporated into multiple marketed partner products, including subcutaneous formulations in oncology, immunology, and rare disease. Products such as DARZALEX SC and VYVGART Hytrulo generate recurring royalty revenue while partners retain responsibility for clinical development and commercialization.
Hypercon and High-Concentration Formulations
The Hypercon platform is designed to create highly concentrated biologic formulations that may support lower injection volumes and more flexible administration. Halozyme is pursuing multi-target collaborations to establish Hypercon as a complementary solution for medicines that cannot be optimally delivered with conventional formulations.
Expanded Injectable Technologies
Acquisitions of Antares Pharma, Elektrofi, and Surf Bio have broadened Halozyme into autoinjectors, wearable delivery systems, microparticle suspensions, and additional formulation technologies. The resulting portfolio addresses both volume and concentration constraints across subcutaneous and self-administered medicines.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。